Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate-specific antigen: current status.

M K Brawer1

  • 1Northwest Prostate Institute, Northwest Hospital, Seattle, WA, USA.

CA: a Cancer Journal for Clinicians
|February 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prostate cancer: epidemiology and screening.

Reviews in urology·2006
Same author

Modern brachytherapy for localized prostate cancers: the northwest hospital (Seattle) experience.

Reviews in urology·2006
Same author

The evolution of hormonal therapy for prostatic carcinoma.

Reviews in urology·2006
Same author

Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer.

Reviews in urology·2006
Same author

Prostate cancer: serum and tissue markers.

Reviews in urology·2006
Same author

Prostate cancer: risk assessment and diagnostic approaches.

Reviews in urology·2006
Same journal

Extranodal natural killer/T-cell lymphoma: From fatal to curable.

CA: a cancer journal for clinicians·2026
Same journal

Systemic amyloid light-chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates.

CA: a cancer journal for clinicians·2026
Same journal

Colorectal cancer screening: An update to the American Cancer Society guideline, 2026.

CA: a cancer journal for clinicians·2026
Same journal

Twenty-year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer.

CA: a cancer journal for clinicians·2026
Same journal

Nonpharmacologic interventions for managing distress, anxiety, and depression for patients with cancer and their family caregivers: A systematic review and meta-analysis.

CA: a cancer journal for clinicians·2026
Same journal

Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.

CA: a cancer journal for clinicians·2026
See all related articles

Prostate-specific antigen (PSA) is a key tumor marker for early prostate cancer detection and management. Advanced PSA derivatives and molecular forms improve diagnostic specificity for malignancy.

Area of Science:

  • Oncology
  • Urology
  • Biochemistry

Background:

  • Prostate-specific antigen (PSA) is a crucial tumor marker for managing prostate diseases.
  • Early detection of prostate cancer, a common neoplasm, relies heavily on PSA.
  • Significant research has advanced prostate cancer management over the last decade.

Purpose of the Study:

  • To review the features of Prostate-specific antigen (PSA).
  • To emphasize strategies for improving PSA's utility in prostate cancer diagnosis.
  • To discuss advancements in PSA assays and their role in malignancy detection.

Main Methods:

  • Review of existing literature on Prostate-specific antigen (PSA).
  • Discussion of PSA derivatives: age-specific PSA, PSA velocity, and PSA density.

Related Experiment Videos

  • Analysis of molecular forms of PSA, including free-to-total PSA ratio and complex PSA.

    • Main Results:

    • PSA is vital for early detection and management of prostate cancer.
    • PSA derivatives offer improved diagnostic capabilities.
    • Molecular forms like free-to-total PSA and complex PSA enhance specificity for malignancy.

    Conclusions:

    • Prostate-specific antigen (PSA) plays a pivotal role in prostate cancer management.
    • Advancements in PSA assays and derivatives have significantly improved diagnostic specificity.
    • The discovery and measurement of PSA represent a major breakthrough in treating prostate cancer.